biotech · Lupus Nephritis - WHO Class III · Non Hodgkin Lymphoma · ARTV
Artiva Biotherapeutics
Artiva Biotherapeutics is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker ARTV. Primary therapeutic focus areas include Lupus Nephritis - WHO Class III, Non Hodgkin Lymphoma, Rheuma
San Diego, USA HQ
2019 Founded
105 Employees
Public company Type
ARTV · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2019
- Employees
- 105
- Programs
- 8
- Drugs
- 9
- Patents
- 0
AFM13
Phase 2 · small molecule · Relapsed or Refractory Hodgkin Lymphoma
AFM13 for Relapsed or Refractory Hodgkin Lymphoma is a Phase 2 program (small_molecule) at Artiva Biotherapeutics with 1 ClinicalTrials.gov record(s).
Internal code AFM13-203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Artiva Biotherapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Relapsed or Refractory Hodgkin Lymphoma
- Status
- terminated
- Trials
- 1